Sleep Disorders

An expert discusses how the risks of benzodiazepine prescribing have been exaggerated in the minds of government officials, critics, and the public at large.

Andrew Krystal, MD, and Wayne Drevets, MD, share their thoughts on the recent seltorexant data presented at the 2024 ASCP Annual Meeting.

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study on the treatment for depressive symptoms in this patient population.

Research on MDD treatments seltorexant and Spravato (esketamine) CIII nasal spray shared at 2024 ASCP Annual Meeting.

Improving cognitive function is a primary goal of brain injury rehabilitation and is made possible through the process of neuroplasticity.

Understanding the heterogeneity and complexities of the histamine monoamine system.

Here are highlights from the fourth day of this year’s APA Annual Meeting.

The experts weighed in on a wide variety of psychiatric issues for the April issue of Psychiatric Times.

In this CME article, discuss and describe the epidemiology, assessment, and evidence-based treatment of insomnia in older adults.

Elena Koundourakis, the head of the Orexin Franchise Development and Portfolio Strategy at Takeda, shares her thoughts on the recent positive topline results from a phase 2 trial evaluating TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.

New positive data on TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.

From the impact of BMI on clinical features of bipolar disorder to FDA approval of the first integrated TMS system for MDD and OCD, here are highlights from the week in Psychiatric Times.

Here’s how we can help improve quality of sleep in both our patients and ourselves.

What is new in research on sleep?

What is new in research on seasonal affective disorder?

Did you miss the 2023 Annual Psychiatric Times World CME Conference? Don't worry, we've got you covered.

What is new in research on ADHD?

From sleep disturbances in ADHD to psychotherapy for treatment-resistant depression, here are highlights from the week in Psychiatric Times.

What is the impact of ADHD on sleep? Researchers performed a systematic review and meta-analysis of objectively measured sleep in children and adolescents with ADHD.

"During the past 5 years has gabapentin retained its position as one of the top 10 drugs prescribed in the United States."

From sleep and neuroendocrine function following TBI to new phase 3 results from a clinical trial evaluating a promising new schizophrenia treatment, here are highlights from the week in Psychiatric Times.

Sleep and neuroendocrine function are disrupted following TBI.

What are the treatment options for insomnia when avoiding benzodiazepines? John W. Winkelman MD, PhD, shares insights and guidance at the 2023 Annual Psychiatric Times World CME Conference.

From long-acting injectable antipsychotics for managing schizophrenia to mental health responses to the recent conflict in Israel, here are highlights from the week in Psychiatric Times.

What is new in research on schizophrenia?

The newest class of medications to treat insomnia have many advantages.

What is the nature of the relationship between psychosis and sleep disorders?

Does early improvement in insomnia predict response to pharmacotherapy in psychotic depression? Authors performed a secondary analysis of a randomized clinical trial.

"Cumulatively, the findings of such reports have led to a concerted effort to encourage physicians to monitor patients for manic symptoms on initiation, reintroduction, and dose modulation of corticosteroid therapy."

What is new in research on sleep?